Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap)

Michael T. Brady, Carrie L. Byington, H. Dele Davies, Kathryn M. Edwards, Mary P. Glode, Mary Anne Jackson, Harry L. Keyserling, Yvonne A. Maldonado, Dennis L Murray, Walter A. Orenstein, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis

Research output: Contribution to journalShort survey

12 Citations (Scopus)

Abstract

The American Academy of Pediatrics and the Centers for Disease Control and Prevention are amending previous recommendations and making additional recommendations for the use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Review of the results from clinical trials and other studies has revealed no excess reactogenicity when Tdap is given within a short interval after other tetanus- or diphtheria-containing toxoid products, and accrual of postmarketing adverse-events reports reveals an excellent safety record for Tdap. Thus, the recommendation for caution regarding Tdap use within any interval after a tetanus- or diphtheriacontaining toxoid product is removed. Tdap should be given when it is indicated and when no contraindication exists. In further efforts to protect people who are susceptible to pertussis, the American Academy of Pediatrics and Centers for Disease Control and Prevention recommend a single dose of Tdap for children 7 through 10 years of age who were underimmunized with diphtheria-tetanus-acellular pertussis (DTaP). Also, the age for recommendation for Tdap is extended to those aged 65 years and older who have or are likely to have contact with an infant younger than 12 months (eg, health care personnel, grandparents, and other caregivers).

Original languageEnglish (US)
Pages (from-to)809-812
Number of pages4
JournalPediatrics
Volume128
Issue number4
DOIs
StatePublished - Oct 1 2011

Fingerprint

Acellular Vaccines
Toxoids
Diphtheria Toxoid
Pertussis Vaccine
Tetanus Toxoid
Tetanus
Whooping Cough
Centers for Disease Control and Prevention (U.S.)
Pediatrics
Diphtheria
Health Personnel
Caregivers
Clinical Trials
Delivery of Health Care
Safety

Keywords

  • Adolescents
  • Adults
  • Diphtheria
  • Infants
  • Pertussis
  • Tdap vaccine
  • Tetanus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Glode, M. P., Jackson, M. A., ... Zaoutis, T. E. (2011). Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Pediatrics, 128(4), 809-812. https://doi.org/10.1542/peds.2011-1752

Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). / Brady, Michael T.; Byington, Carrie L.; Davies, H. Dele; Edwards, Kathryn M.; Glode, Mary P.; Jackson, Mary Anne; Keyserling, Harry L.; Maldonado, Yvonne A.; Murray, Dennis L; Orenstein, Walter A.; Schutze, Gordon E.; Willoughby, Rodney E.; Zaoutis, Theoklis E.

In: Pediatrics, Vol. 128, No. 4, 01.10.2011, p. 809-812.

Research output: Contribution to journalShort survey

Brady, MT, Byington, CL, Davies, HD, Edwards, KM, Glode, MP, Jackson, MA, Keyserling, HL, Maldonado, YA, Murray, DL, Orenstein, WA, Schutze, GE, Willoughby, RE & Zaoutis, TE 2011, 'Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap)', Pediatrics, vol. 128, no. 4, pp. 809-812. https://doi.org/10.1542/peds.2011-1752
Brady, Michael T. ; Byington, Carrie L. ; Davies, H. Dele ; Edwards, Kathryn M. ; Glode, Mary P. ; Jackson, Mary Anne ; Keyserling, Harry L. ; Maldonado, Yvonne A. ; Murray, Dennis L ; Orenstein, Walter A. ; Schutze, Gordon E. ; Willoughby, Rodney E. ; Zaoutis, Theoklis E. / Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). In: Pediatrics. 2011 ; Vol. 128, No. 4. pp. 809-812.
@article{c2a95c5fa7274e47a394b0179e6ebad7,
title = "Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap)",
abstract = "The American Academy of Pediatrics and the Centers for Disease Control and Prevention are amending previous recommendations and making additional recommendations for the use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Review of the results from clinical trials and other studies has revealed no excess reactogenicity when Tdap is given within a short interval after other tetanus- or diphtheria-containing toxoid products, and accrual of postmarketing adverse-events reports reveals an excellent safety record for Tdap. Thus, the recommendation for caution regarding Tdap use within any interval after a tetanus- or diphtheriacontaining toxoid product is removed. Tdap should be given when it is indicated and when no contraindication exists. In further efforts to protect people who are susceptible to pertussis, the American Academy of Pediatrics and Centers for Disease Control and Prevention recommend a single dose of Tdap for children 7 through 10 years of age who were underimmunized with diphtheria-tetanus-acellular pertussis (DTaP). Also, the age for recommendation for Tdap is extended to those aged 65 years and older who have or are likely to have contact with an infant younger than 12 months (eg, health care personnel, grandparents, and other caregivers).",
keywords = "Adolescents, Adults, Diphtheria, Infants, Pertussis, Tdap vaccine, Tetanus",
author = "Brady, {Michael T.} and Byington, {Carrie L.} and Davies, {H. Dele} and Edwards, {Kathryn M.} and Glode, {Mary P.} and Jackson, {Mary Anne} and Keyserling, {Harry L.} and Maldonado, {Yvonne A.} and Murray, {Dennis L} and Orenstein, {Walter A.} and Schutze, {Gordon E.} and Willoughby, {Rodney E.} and Zaoutis, {Theoklis E.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1542/peds.2011-1752",
language = "English (US)",
volume = "128",
pages = "809--812",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

TY - JOUR

T1 - Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap)

AU - Brady, Michael T.

AU - Byington, Carrie L.

AU - Davies, H. Dele

AU - Edwards, Kathryn M.

AU - Glode, Mary P.

AU - Jackson, Mary Anne

AU - Keyserling, Harry L.

AU - Maldonado, Yvonne A.

AU - Murray, Dennis L

AU - Orenstein, Walter A.

AU - Schutze, Gordon E.

AU - Willoughby, Rodney E.

AU - Zaoutis, Theoklis E.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The American Academy of Pediatrics and the Centers for Disease Control and Prevention are amending previous recommendations and making additional recommendations for the use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Review of the results from clinical trials and other studies has revealed no excess reactogenicity when Tdap is given within a short interval after other tetanus- or diphtheria-containing toxoid products, and accrual of postmarketing adverse-events reports reveals an excellent safety record for Tdap. Thus, the recommendation for caution regarding Tdap use within any interval after a tetanus- or diphtheriacontaining toxoid product is removed. Tdap should be given when it is indicated and when no contraindication exists. In further efforts to protect people who are susceptible to pertussis, the American Academy of Pediatrics and Centers for Disease Control and Prevention recommend a single dose of Tdap for children 7 through 10 years of age who were underimmunized with diphtheria-tetanus-acellular pertussis (DTaP). Also, the age for recommendation for Tdap is extended to those aged 65 years and older who have or are likely to have contact with an infant younger than 12 months (eg, health care personnel, grandparents, and other caregivers).

AB - The American Academy of Pediatrics and the Centers for Disease Control and Prevention are amending previous recommendations and making additional recommendations for the use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Review of the results from clinical trials and other studies has revealed no excess reactogenicity when Tdap is given within a short interval after other tetanus- or diphtheria-containing toxoid products, and accrual of postmarketing adverse-events reports reveals an excellent safety record for Tdap. Thus, the recommendation for caution regarding Tdap use within any interval after a tetanus- or diphtheriacontaining toxoid product is removed. Tdap should be given when it is indicated and when no contraindication exists. In further efforts to protect people who are susceptible to pertussis, the American Academy of Pediatrics and Centers for Disease Control and Prevention recommend a single dose of Tdap for children 7 through 10 years of age who were underimmunized with diphtheria-tetanus-acellular pertussis (DTaP). Also, the age for recommendation for Tdap is extended to those aged 65 years and older who have or are likely to have contact with an infant younger than 12 months (eg, health care personnel, grandparents, and other caregivers).

KW - Adolescents

KW - Adults

KW - Diphtheria

KW - Infants

KW - Pertussis

KW - Tdap vaccine

KW - Tetanus

UR - http://www.scopus.com/inward/record.url?scp=80053492337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053492337&partnerID=8YFLogxK

U2 - 10.1542/peds.2011-1752

DO - 10.1542/peds.2011-1752

M3 - Short survey

C2 - 21949151

AN - SCOPUS:80053492337

VL - 128

SP - 809

EP - 812

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

ER -